• Molecular NameCefpodoxime
  • SynonymCefpodoxime proxetil; CPDX-PR; RU 51807
  • Weight427.462
  • Drugbank_IDDB01416
  • ACS_NO82619-04-3
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.0
  • pkaN/A
  • LogD (pH=7, predicted)-3.98
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.61
  • LogSw (predicted, AB/LogsW2.0)1.68
  • Sw (mg/ml) (predicted, ACD/Labs)0.16
  • No.of HBond Donors4
  • No.of HBond Acceptors11
  • No.of Rotatable Bonds7
  • TPSA209.98
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn oral third generation cephalosporin. It is active against most Gram positive and Gram negative organisms. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability50.0
  • Protein binding25.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNegligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver
  • Half life2 h
  • ExcretionRenal, unchanged
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A